Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 4
1999 3
2000 2
2001 2
2002 1
2003 4
2004 3
2005 1
2007 2
2008 3
2009 3
2012 1
2016 1
2017 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span.
Murakami K, Wierzba K, Sano M, Shibata J, Yonekura K, Hashimoto A, Sato K, Yamada Y. Murakami K, et al. Clin Exp Metastasis. 1998 May;16(4):323-31. doi: 10.1023/a:1006561329512. Clin Exp Metastasis. 1998. PMID: 9626811
These effects of TAC-101 were stronger than those of 5-FU, CDDP or ATRA. Furthermore, TAC-101 inhibited the binding of AP-1 to DNA on electrophoretic mobility shift assay using nuclear extract of AZ-521 cells, although ATRA did not inhibit. These findi …
These effects of TAC-101 were stronger than those of 5-FU, CDDP or ATRA. Furthermore, TAC-101 inhibited the bind …
Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma.
Okusaka T, Ueno H, Ikeda M, Takezako Y, Morizane C. Okusaka T, et al. Cancer Sci. 2012 Aug;103(8):1524-30. doi: 10.1111/j.1349-7006.2012.02334.x. Epub 2012 Jun 18. Cancer Sci. 2012. PMID: 22587457 Free PMC article. Clinical Trial.
We conducted a phase I study in Japanese patients with advanced HCC to examine the pharmacokinetics, recommended dose, safety, and efficacy of TAC-101. The administered dose of TAC-101 was 10 mg/day in four patients (level 1), 20 mg/day in six (level 2 …
We conducted a phase I study in Japanese patients with advanced HCC to examine the pharmacokinetics, recommended dose, safety, and efficacy …
Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics.
Huppertz A, Bollmann J, Behnisch R, Bruckner T, Zorn M, Burhenne J, Haefeli WE, Czock D. Huppertz A, et al. Clin Pharmacol Drug Dev. 2021 Aug;10(8):899-907. doi: 10.1002/cpdd.924. Epub 2021 Feb 28. Clin Pharmacol Drug Dev. 2021. PMID: 33641238 Clinical Trial.

The maximum concentration (C(max) ) and the time to maximum concentration (t(max) ) were significantly affected only after IR-Tac (C(max) IR-Tac, 39%; 90%CI, 34%-45%; P < .01; and PR-Tac, 87%; 90%CI, 76%-101%; P = .11; t(max) IR-Tac, 212%, 90%CI, 179%-252%; P < .01; and PR-

The maximum concentration (C(max) ) and the time to maximum concentration (t(max) ) were significantly affected only after IR-Tac (C(max) IR …
TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.
Murakami K, Yamaura T, Suda K, Ohie S, Shibata J, Toko T, Yamada Y, Saiki I. Murakami K, et al. Jpn J Cancer Res. 1999 Nov;90(11):1254-61. doi: 10.1111/j.1349-7006.1999.tb00705.x. Jpn J Cancer Res. 1999. PMID: 10622538 Free PMC article.
The anti-tumor and anti-metastatic effects of 4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid (TAC-101) were investigated using our established lung cancer model. ...The anti-invasive activity of TAC-101 may be involved in its in vivo anti-metastatic …
The anti-tumor and anti-metastatic effects of 4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid (TAC-101) were investigated usi …
A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
Ezawa S, Suzuki N, Ohie S, Higashiguchi A, Hosoi F, Kitazato K, Susumu N, Aoki D. Ezawa S, et al. Gynecol Oncol. 2008 Mar;108(3):627-31. doi: 10.1016/j.ygyno.2007.10.019. Epub 2007 Nov 28. Gynecol Oncol. 2008. PMID: 18048092
The antitumor effect of TAC-101 alone or combined with cisplatin was tested using human ovarian carcinoma. ...The IC50 values of cisplatin and TAC-101 showed a significant correlation (p<0.01). CONCLUSION: These in vitro findings suggest that a comb …
The antitumor effect of TAC-101 alone or combined with cisplatin was tested using human ovarian carcinoma. ...The IC50 values …
Contribution of AP-1 interference induced by TAC-101 to tumor growth suppression in a hepatocellular carcinoma model.
Eshima K, Fukaya S, Sugimoto A, Mori T, Yokoi H, Yamamoto Y, Sugiura S, Honda S, Masuko N, Murakami K, Yamasaki Y, Kagechika H. Eshima K, et al. Tumour Biol. 2009;30(1):1-7. doi: 10.1159/000189712. Epub 2009 Jan 12. Tumour Biol. 2009. PMID: 19142034
Here, we demonstrate the contribution of TAC-101-induced AP-1 interference to stabilization of tumor growth. ...In contrast to JHH-7, JHH-6 is another RARalpha-expressing human hepatocellular carcinoma (HCC) cell line with constitutive activation of AP-1, but it is …
Here, we demonstrate the contribution of TAC-101-induced AP-1 interference to stabilization of tumor growth. ...In contrast to …
A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
Suzuki N, Aoki D, Oie S, Horiuchi M, Hasegawa Y, Ezawa S, Suzuki A, Susumu N, Hosoi F, Kitazato K, Nozawa S. Suzuki N, et al. Gynecol Oncol. 2004 Sep;94(3):643-9. doi: 10.1016/j.ygyno.2004.06.026. Gynecol Oncol. 2004. PMID: 15350353
A caspase inhibitor blocked the induction of apoptosis by TAC-101. The maximum inhibition of RMG-II tumor growth in nude mice by TAC-101, cisplatin, and paclitaxel was 45%, 34%, and 47%, respectively. CONCLUSION: Oral TAC-101 shows potent …
A caspase inhibitor blocked the induction of apoptosis by TAC-101. The maximum inhibition of RMG-II tumor growth in nude mice …
TAC-101, a novel retinobenzoic-acid derivative, enhances gap junctional intercellular communication among renal epithelial cells treated with renal carcinogens.
Miyaguchi T, Nomata K, Noguchi M, Watanabe J, Satoh H, Kanetake H. Miyaguchi T, et al. Anticancer Res. 2001 Nov-Dec;21(6A):4025-30. Anticancer Res. 2001. PMID: 11911287
[4-3,5-Bis(trimethylsilyl)benzamido] benzoic acido] (TAC-101), which exhibits an anti-tumor effect, can bind to retinoic acid receptors (RARs). ...Consequently, TAC-101 prevented the disruption of GJIC in MDCK cells. These data suggested that TAC
[4-3,5-Bis(trimethylsilyl)benzamido] benzoic acido] (TAC-101), which exhibits an anti-tumor effect, can bind to retinoic acid …
A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.
Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. Higginbotham KB, et al. J Cancer Res Clin Oncol. 2008 Dec;134(12):1325-35. doi: 10.1007/s00432-008-0406-2. Epub 2008 May 27. J Cancer Res Clin Oncol. 2008. PMID: 18504614 Clinical Trial.
PURPOSE: Preclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has anti-tumor activity in hepatocellular carcinoma (HCC). ...Significant disease stabilization (12/21 pts, 57%), 2 late PRs, and prolonged M …
PURPOSE: Preclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, h …
4- [3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line.
Inoue Y, Nakayama Y, Sako T, Minagawa N, Abe Y, Nagato M, Kadowaki K, Katsuki T, Matsumoto K, Tsurudome Y, Shibao K, Hirata K, Nagata N. Inoue Y, et al. In Vivo. 2007 Mar-Apr;21(2):381-7. In Vivo. 2007. PMID: 17436592 Free article.
In this study, the induction of apoptosis-related proteins and the activities of caspases in a DLD-1 cell line under medication with TAC-101 were investigated. MATERIALS AND METHODS: DLD-1 cells were cultured with different concentrations of TAC-101 fo …
In this study, the induction of apoptosis-related proteins and the activities of caspases in a DLD-1 cell line under medication with TAC
32 results